Segment Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-218,841
| Closed | -$11.2M | – | 220 |
|
|
2022
Q4 | $11.2M | Buy |
218,841
+6,621
| +3% | +$317K | 1.3% | 24 |
|
|
2022
Q3 | $9.29M | Buy |
212,220
+11,761
| +6% | +$571K | 1.16% | 28 |
|
|
2022
Q2 | $10.5M | Buy |
200,459
+9,427
| +5% | +$480K | 1.33% | 21 |
|
|
2022
Q1 | $9.89M | Buy |
191,032
+12,468
| +7% | +$647K | 1.02% | 35 |
|
|
2021
Q4 | $10.5M | Buy |
178,564
+3,278
| +2% | +$162K | 1.11% | 25 |
|
|
2021
Q3 | $7.54M | Buy |
175,286
+2,948
| +2% | +$131K | 0.89% | 45 |
|
|
2021
Q2 | $6.75M | Buy |
172,338
+9,477
| +6% | +$369K | 0.8% | 54 |
|
|
2021
Q1 | $5.9M | Buy |
162,861
+8,979
| +6% | +$319K | 0.78% | 55 |
|
|
2020
Q4 | $5.66M | Sell |
153,882
-15,956
| -9% | -$585K | 0.82% | 53 |
|
|
2020
Q3 | $5.91M | Buy |
169,838
+3,033
| +2% | +$106K | 0.96% | 41 |
|
|
2020
Q2 | $5.17M | Buy |
166,805
+3,594
| +2% | +$122K | 0.96% | 40 |
|
|
2020
Q1 | $5.05M | Sell |
163,211
-1,162
| -0.7% | -$39.6K | 1.13% | 32 |
|
|
2019
Q4 | $6.11M | Buy |
164,373
+12,959
| +9% | +$462K | 1.03% | 30 |
|
|
2019
Q3 | $5.16M | Buy |
151,414
+4,112
| +3% | +$150K | 1.01% | 31 |
|
|
2019
Q2 | $6.05M | Buy |
147,302
+2,181
| +2% | +$86.6K | 1.23% | 20 |
|
|
2019
Q1 | $5.85M | Buy |
145,121
+7,825
| +6% | +$313K | 1.24% | 17 |
|
|
2018
Q4 | $5.69M | Sell |
137,296
-12,917
| -9% | -$536K | 1.43% | 14 |
|
|
2018
Q3 | $6.28M | Buy |
150,213
+336
| +0.2% | +$12.9K | 1.37% | 12 |
|
|
2018
Q2 | $5.16M | Buy |
149,877
+1,740
| +1% | +$59.5K | 1.22% | 15 |
|
|
2018
Q1 | $4.99M | Buy |
148,137
+1,033
| +0.7% | +$35.5K | 1.24% | 17 |
|
|
2017
Q4 | $5.05M | Buy |
147,104
+2,454
| +2% | +$83.7K | 1.22% | 19 |
|
|
2017
Q3 | $4.9M | Buy |
144,650
+9,730
| +7% | +$313K | 1.3% | 13 |
|
|
2017
Q2 | $4.3M | Buy |
134,920
+13,808
| +11% | +$435K | 1.18% | 20 |
|
|
2017
Q1 | $3.93M | Buy |
121,112
+1,622
| +1% | +$51.1K | 1.28% | 17 |
|
|
2016
Q4 | $3.68M | Buy |
119,490
+1,861
| +2% | +$56.8K | 1.35% | 19 |
|
|
2016
Q3 | $3.78M | Sell |
117,629
-337
| -0.3% | -$11.3K | 1.49% | 16 |
|
|
2016
Q2 | $3.94M | Sell |
117,966
-12,189
| -9% | -$389K | 1.63% | 14 |
|
|
2016
Q1 | $3.66M | Buy |
130,155
+1,338
| +1% | +$38.2K | 1.37% | 20 |
|
|
2015
Q4 | $3.94M | Sell |
128,817
-1,871
| -1% | -$58.9K | 1.5% | 16 |
|
|
2015
Q3 | $3.9M | Buy |
130,688
+5,593
| +4% | +$179K | 1.49% | 17 |
|
|
2015
Q2 | $3.98M | Sell |
125,095
-27
| -0% | -$880 | 1.38% | 16 |
|
|
2015
Q1 | $4.13M | Buy |
125,122
+20,128
| +19% | +$640K | 1.38% | 15 |
|
|
2014
Q4 | $3.1M | Buy |
104,994
+3,005
| +3% | +$86.2K | 1.19% | 23 |
|
|
2014
Q3 | $2.86M | Buy |
101,989
+5,293
| +5% | +$149K | 1.09% | 23 |
|
|
2014
Q2 | $2.72M | Buy |
96,696
+3,736
| +4% | +$106K | 1.05% | 24 |
|
|
2014
Q1 | $2.83M | Buy |
92,960
+7,995
| +9% | +$238K | 1.32% | 18 |
|
|
2013
Q4 | $2.47M | Buy |
84,965
+3,248
| +4% | +$94.5K | 1.22% | 20 |
|
|
2013
Q3 | $2.23M | Buy |
81,717
+2,431
| +3% | +$66.1K | 1.21% | 20 |
|
|
2013
Q2 | $2.11M | Buy |
+79,286
| New | +$2.19M | 1.26% | 17 |
|
Other funds holding PFE
Segment Wealth Management's PFE Position: Q1 2023 in Review
Segment Wealth Management sold out of Pfizer (PFE) in Q1 2023, closing a stake of 218,841 shares — an estimated $11.2M sold.
Segment Wealth Management first reported a position in PFE in Q2 2013 and held it in 39 quarters. The position peaked at $11.2M in Q4 2022. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.
- Segment Wealth Management reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
- Segment Wealth Management sold 218,841 Pfizer shares in Q1 2023, an estimated $11.2M.
- Segment Wealth Management first reported a position in Pfizer in Q2 2013 and held it in 39 quarters.
- Segment Wealth Management's Pfizer position peaked at $11.2M in Q4 2022.
- 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.
Based on Segment Wealth Management's 13F filing for Q1 2023, filed 20 Apr 2023.